title: Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes.
abstract: Our aim was to evaluate the activity and toxicity of capecitabine and cisplatin (CapCisp) combination in anthracycline- and taxane-pretreated metastatic breast cancer patients. Thirty-three patients, 20-61 years of age (median 41), were included. They received Cap 2,000 mg/m(2) on days 1-14 and Cisp 60 mg/m(2) on day 1, repeated every 3 weeks. Twelve nonprogressive patients continued single-agent Cap therapy until progression or until intolerable toxicity after Cisp cessation. The disease control rate in 154 cycles was 81.8%: complete response 3.0% (n = 1), partial response 48.5% (n = 16) and stable disease 30.3% (n = 10). The median time to disease progression was 6.3 months (95% CI 3.8-8.8). The median overall survival was 11.5 months (95% CI 6.9-16.1). The only grade 3 toxicity was neutropenia, observed in 4 patients (12.1%). CapCisp has an encouraging anti-tumor activity with a low toxicity rate in anthracycline- and taxane-pretreated metastatic breast cancer patients.
authors: Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey.
authors: Berna
authors: B
authors: Oksuzoglu
authors: Huseyin
authors: H
authors: Abali
authors: Mutlu
authors: M
authors: Hayran
authors: Nuriye
authors: N
authors: Yildirim
authors: Burcin
authors: B
authors: Budakoglu
authors: Nurullah
authors: N
authors: Zengin
mesh_terms: D000328:Adult; D018943:Anthracyclines / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D000069287:Capecitabine; D002945:Cisplatin / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018450:Disease Progression; D004361:Drug Tolerance; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D018943:Anthracyclines; D001952:Bridged-Ring Compounds; D043823:Taxoids; D003841:Deoxycytidine; C080625:taxane; D000069287:Capecitabine; D002945:Cisplatin; D005472:Fluorouracil